301301.SHE Yili Chuanning Biotechnology Co. Ltd. A
- Market cap
- CNY 16.5B
- P/E
- 32.2x
- P/B
- 2.01x
- ROE
- 5.5%
- Dividend yield
- 3.76%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301301.SHE undervalued?
Graham number301301.SHE trades 69.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Yili Chuanning Biotechnology Co. Ltd. A fundamental analysis
No fundamental analysis for Yili Chuanning Biotechnology Co. Ltd. A yet.
Yili Chuanning Biotechnology Co. Ltd. A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Yili Chuanning Biotechnology Co. Ltd. A
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminop…
Full company profileYili Chuanning Biotechnology Co. Ltd. A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Yili Chuanning Biotechnology Co. Ltd. A annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 3.23B | 3.82B | 4.82B | 5.76B | 4.62B | 3.84B |
| Gross Profit | 718M | 947M | 1.52B | 2.10B | 1.35B | 932M |
| Operating Income | 408M | 708M | 1.24B | 1.76B | 1.02B | 627M |
| EBITDA | - | 1.18B | 1.76B | 2.28B | 1.56B | 577M |
| Net Income | 111M | 412M | 941M | 1.40B | 769M | 443M |
| EPS | 0.06 | 0.19 | 0.42 | 0.63 | 0.34 | 0.20 |
| Balance Sheet | ||||||
| Total Assets | 9.46B | 10.4B | 10.1B | 10.6B | 10.4B | 10.4B |
| Total Liabilities | 4.68B | 4.18B | 3.17B | 2.64B | 2.32B | 2.30B |
| Shareholders' Equity | 4.77B | 6.20B | 6.96B | 7.90B | 8.08B | 8.04B |
| Cash & Short-term Investments | 510M | 1.63B | 761M | 1.09B | 734M | 735M |
| Cash Flow | ||||||
| Operating Cash Flow | 803M | 692M | 1.29B | 1.79B | 549M | - |
| Capital Expenditure | 52.3M | 47.2M | 345M | 42.6M | 97.2M | 71.1M |
| Free Cash Flow | 751M | 644M | 947M | 1.75B | 452M | 1.03B |
| Ratios | ||||||
| ROE | 2.3% | 6.6% | 13.5% | 17.7% | 9.5% | 5.5% |
| ROA | 1.2% | 4.0% | 9.3% | 13.3% | 7.4% | 4.3% |
| Net Profit Margin | 3.4% | 10.8% | 19.5% | 24.3% | 16.7% | 11.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Yili Chuanning Biotechnology Co. Ltd. A dividends
- Dividend yield
- 3.76%
- Forward dividend
- 0.17 CNY
- Payout ratio
- 80.9%
- Ex-dividend date
- Apr 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 622M | 0.28 | 80.9% |
| 2024 | CNY 545M | 0.24 | 38.9% |
| 2023 | CNY 290M | 0.13 | 30.8% |
| 2022 | CNY 143M | 0.06 | 34.7% |
| 2021 | CNY 168M | 0.08 | 150.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Yili Chuanning Biotechnology Co. Ltd. A
- Insiders 75.15%
- Institutions 1.13%
- Public & others 23.72%
- Shares outstanding 2.23B
- Free float 527M
Yili Chuanning Biotechnology Co. Ltd. A company profile
- Company name
- Yili Chuanning Biotechnology Co. Ltd. A
- Ticker
- 301301.SHE
- ISIN
- CNE100005WX0
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,126
- Fiscal year end
- December
- Address
- No. 1 Gongchen Road, Yining, China, 835000
- Phone
- 86 28 8286 0516
- Website
- klcnsw.com
About Yili Chuanning Biotechnology Co. Ltd. A
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ectoine, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop cultivation, detection, technical consultation, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Yili Chuanning Biotechnology Co. Ltd. A management
7- Mr. Xuheng DengGM & Director · born 1987
- Mr. Yixing LiDeputy GM, CFO & Director · born 1984
- Mr. Zhao HuaDeputy GM & Chief Scientist · born 1970
- Mr. Xiang GuDeputy GM & Secretary · born 1992
- Mr. Hai JiangDeputy General Manager · born 1982
- Mr. Yun Peng ShenDeputy General Manager · born 1972
- Yan NiuAccounting Supervisor